Status:

WITHDRAWN

Scopolamine Treatment for Patients With Organophosphate Poisoning

Lead Sponsor:

Assaf-Harofeh Medical Center

Collaborating Sponsors:

Israeli MOH

International Diabetes Federation

Conditions:

Neurotoxicity Syndromes

Eligibility:

All Genders

2-60 years

Phase:

NA

Brief Summary

Organophosphate (OP) compounds are a major threat as chemical warfare agents or in terrorist act. OPs are also the active ingredient of many insecticides. Ingestion of insecticides is a common cause o...

Detailed Description

Objective: to determine whether adding scopolamine to the standard treatment of atropine and oximes improve the outcome of patients with OP poisoning and CNS manifestations. Design: A multi-center, ra...

Eligibility Criteria

Inclusion

  • Age: 2- 60 years
  • At least two of the following three criteria:
  • Known exposure to an organophosphate or carbamate insecticide in the last 72 hours.
  • Symptoms and signs typical to organophosphate poisoning involving at least two systems (gastrointestinal, respiratory, skin, eyes,) See appendix
  • Low levels of plasma butyrylcholinesterase (less than 50% of the lower normal range )
  • CNS involvement in the first 72 hours after exposure: determined by finding at least one of the following major criteria or at least two of the minor criteria
  • Major criteria for CNS involvement:
  • Seizures
  • Extrapyramidal or Parkinson like symptoms
  • Decreased level of consciousness (GCS\< 12)
  • Minor criteria for CNS involvement:
  • GCS 14-12
  • Confusion
  • Hallucinations

Exclusion

  • Hypersensitivity to scopolamine
  • Glaucoma, narrow-angle (angle-closure)
  • Tachyarrhythmias, congestive heart failure
  • Obstructive gastrointestinal disease
  • Myasthenia Gravis
  • Reflux esophagitis
  • Ulcerative colitis
  • Known obstructive uropathy
  • Pregnancy
  • Patient or legal guardian unable to give informed consent (see comment under ethics)
  • Severe co-morbidity (multi-trauma, advanced cancer, etc)

Key Trial Info

Start Date :

October 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2009

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT00389259

Start Date

October 1 2007

End Date

December 1 2009

Last Update

April 5 2011

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Rambam Hospital

Haifa, Israel

Scopolamine Treatment for Patients With Organophosphate Poisoning | DecenTrialz